Mayo Clinic researchers have developed a process that uses human cells as inks, dubbed bioinks, to print natural tissue-like structures in three dimensions.
Could 3D technology lead to a new treatment for inflammatory skin disease? Mayo Clinic researchers believe the answer is yes. They’ve developed a 3D prototype they describe as “the most human-like skin model” for studying atopic dermatitis and other skin conditions.
Saranya Wyles, M.D., Ph.D.
The 3D technology brings new options, says Saranya Wyles, M.D., Ph.D., a dermatologist, in a Mayo Clinic press release. “It can create human equivalents that are truer and more representative of the disease, unlike the animal models we have worked with in the past. Inflammatory skin diseases and rare diseases can be modeled for better understanding of the underlying pathology and drug testing and how that might affect the patient."
The process they’re using is bioprinting, which uses human cells as inks, called bioinks, to print natural tissue-like structures in three dimensions. The bioinks act much like ink from a printer ink cartridge.
“We can print the skin from cells of patients with atopic dermatitis or eczema," says Wyles, who is the senior author of a report about the prototype in Regenerative Biomaterials. "Our system allows us to use up to six different cell types to model and recreate human skin tissue."
The printing process is “sort of like creating layers of a tiered cake with different cell types," Wyles adds. "You start at the bottom (the dermis), then you add the next layer (the epidermis), and the scaffold material acts as the frosting to connect the layers. The printed skin is put into an incubator where the cells can communicate with each other, expand and form bioprinted skin."
© rasahdashurov stock.adobe.com
However, the researchers have their job cut out for them. Three-dimensional bioprinting uses biomaterials, cells and culturing techniques to create “biologically equivalent models with key features to replicate the phenotype and function of the desired organ.” That means incorporating many types of cells, including melanocytes (which form skin pigment), keratinocytes (which allow for skin renewal), and fibroblasts (which form a connective tissue). The cells are printed in layers that stratify and mature into full layers of skin. The 3D bioprinting model will need to replicate that complexity, but has yet to incorporate the sweat glands, blood vessels, skin follicles and nerves found in native human tissue, the researchers say. Also, the biomaterial needs specific characteristics: For instance, in the case of grafts for blistering skin conditions, the biomaterial should have strong water-biomaterial interactions that modulate cell adhesion—without that, the bioink may not be compatible with the grafted site and will be rejected.
The technology has the potential to transform clinical and laboratory practice, Wyles says. "This 3D model more accurately recreates disease, creates surgical grafts and provides the ability to test new therapies." More research is needed, though, to bioprint an exact replica of “patient-specific” human skin with atopic dermatitis.
Insights Into Chronic Itch From Shawn Kwatra, M.D.
April 15th 2025A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how treatment options are improving and the challenges patients face in getting access to the right therapies.
Read More
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Opzelura Topical Cream Drives Incyte's Record Growth in 2024 with 50% Revenue Surge
February 18th 2025Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat mild to moderate atopic dermatitis in patients 12 and older who are not immunocompromised.
Read More